



Post. and Mail
BOX AF

CFW AF 1623
RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE


Applicants : Kunzo SUNAMOTO et al
Title : HIGH PURITY POLYSACCHARIDE CONTAINING A
HYDROPHOBIC GROUP AND PROCESS FOR PRODUCING IT
Serial No. : 10/091 992 Group: 1623
Confirmation No.: 8077
Filed : March 6, 2002 Examiner: Lewis
Atty. Docket No.: Yanagihara Case 49A

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FIRST CLASS MAILING CERTIFICATE

Sir:

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR 1.8 as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450, on June 18, 2004.


Terryence F. Chapman

TFC/smd

| | | |
|--------------------------|-------------------------|-----------------|
| FLYNN, THIEL, BOUTELL | Dale H. Thiel | Reg. No. 24 323 |
| & TANIS, P.C. | David G. Boutell | Reg. No. 25 072 |
| 2026 Rambling Road | Ronald J. Tanis | Reg. No. 22 724 |
| Kalamazoo, MI 49008-1631 | Terryence F. Chapman | Reg. No. 32 549 |
| Phone: (269) 381-1156 | Mark L. Maki | Reg. No. 36 589 |
| Fax: (269) 381-5465 | Liane L. Churney | Reg. No. 40 694 |
| | Brian R. Tumm | Reg. No. 36 328 |
| | Steven R. Thiel | Reg. No. 53 685 |
| | Sidney B. Williams, Jr. | Reg. No. 24 949 |

Correspondence: Supplemental Amendment After Final Rejection
dated June 18, 2004
including enclosures listed thereon

190.05/03



RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE

IN THE U.S. PATENT AND TRADEMARK OFFICE

June 18, 2004

Applicants: Junzo SUNAMOTO et al

For: HIGH PURITY POLYSACCHARIDE CONTAINING A
HYDROPHOBIC GROUP AND PROCESS FOR PRODUCING IT

Serial No.: 10/091 992 Group: 1623

Confirmation No.: 8077

Filed: March 6, 2002 Examiner: Lewis

Atty. Docket No.: Yanagihara Case 49A

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT AFTER FINAL REJECTION

Sir:

Further to the Amendment After Final Rejection dated May 24, 2004, Applicants are enclosing herewith an executed copy of the Declaration Under 37 CFR 1.132. As pointed out in the previously filed Amendment After Final Rejection, the enclosed Declaration Under 37 CFR 1.132 compares a cholesterol-substituted polysaccharide derivative according to the Akiyoshi et al reference with a polysaccharide derivative of the present invention prepared according to Example 1-3 in the present specification. As shown in the enclosed Declaration Under 37 CFR 1.132, the cholesterol derivative prepared according to the Akiyoshi et al reference had a much higher impurity content than that of the present invention. Since the hydrophobic group-contained polysaccharide of the present invention is used as a material in medical use, such as a coating material for coating a drug-carrier enclosing medicaments, the very high purity achieved by the present invention clearly is an unexpected advantage and establishes the patentability of the presently claimed invention over the

prior art cited by the Examiner. Favorable consideration is respectfully solicited.

Respectfully submitted,


Terryence F. Chapman

TFC/smd

| | | |
|--------------------------|-------------------------|-----------------|
| FLYNN, THIEL, BOUTELL | Dale H. Thiel | Reg. No. 24 323 |
| & TANIS, P.C. | David G. Boutell | Reg. No. 25 072 |
| 2026 Rambling Road | Ronald J. Tanis | Reg. No. 22 724 |
| Kalamazoo, MI 49008-1631 | Terryence F. Chapman | Reg. No. 32 549 |
| Phone: (269) 381-1156 | Mark L. Maki | Reg. No. 36 589 |
| Fax: (269) 381-5465 | Liane L. Churney | Reg. No. 40 694 |
| | Brian R. Tumm | Reg. No. 36 328 |
| | Steven R. Thiel | Reg. No. 53 685 |
| | Sidney B. Williams, Jr. | Reg. No. 24 949 |

Encl: Executed Declaration Under 37 CFR 1.132
Postal Card

136.05/04



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of

Hiroki FUKUI

Application/Control No. 10/091,992, filed: 31/03/1999

for: HIGH PURITY POLYSACCHARIDE CONTAINING HYDROPHOBIC
GROUP AND PROCESS FOR PRODUCING IT

Honorable Commissioner of Patents and Trademarks

United States Patent and Trademark Office

Washington, D. C. 20231

Sir:

DECLARATION UNDER 37 CFR 1.132

I, Hiroki FUKUI, declare and state that:

1. I am one of Inventors of the present invention.
2. Concerning the above-identified application, I carried out the following experiment.

Experiment

Comparative Example 2

By the same procedures as in Example 1-2, a pullulan-cholesterol derivative was synthesized. After completion of the reaction, a superfluous amount of ethanol was introduced into the reaction liquor to cause formation of precipitate, which was purified in the following manner. Thus, the supernatant liquid was removed and ethanol was added to the remaining precipitate, whereupon the precipitate was collected by filtration and was subjected to vacuum drying. 0.5 g of the so-obtained white powder was taken out and was dissolved in 200 ml of pure water. The resulting aqueous solution was once ultrasonicated to disperse the contents therein uniformly, whereupon the solution was charged in a dialysis membrane (Spectra/Por 3: a product of the firm Spectrapor; exclusion molecular weight of 3,500) to subject to a dialysis against about 10 liters of pure water. The dialysis was continued for five days while exchanging pure water once a day. After the dialysis, the resulting liquid was subjected to a freeze-drying, whereby about 0.4 gram of white powdery product was obtained.

The above purified product was analyzed by ^1H -NMR as in Example 1-2 to determine the content of the cholesterol dimer. On the other hand, a sample before the ultrasonication and the purified product were analyzed by SEC in the same manner as in Example 1-3. The results were as shown in Table 9.

Table 9

| | |
|--|------------|
| Content of unsubstituted pullulan | 3.6 wt. % |
| Content of cholesterol dimer | 0.5 wt. % |
| Content of CHP in the purified product | 95.9 wt. % |

In Example 1-2, cholesterol dimer was removed completely by acetone-reprecipitation, whereas in Comparative Example 2 using ethanol-reprecipitation, a considerable amount of cholesterol dimer remained. In Example 1-3, unsubstituted pullulan was removed by ultracentrifugation, whereas in Comparative Example 2 using dialysis, removal thereof was failed.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-referenced application or any patent issuing thereon.

Date: June 2, 2004

Hiroki Fukui

Hiroki FUKUI